ReviewThe Korean journal of laboratory medicine2011
Myelomatous pleural effusion: a case series in a single institution and literature review.
Review in The Korean journal of laboratory medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Features which discriminate between tuberculosis and haematologic malignancy as the cause of pleural effusions with high adenosine deaminase.Respiratory research · 2024Observational
- Article
- Case Report: A very rare case of a Pleural Effusion revealing Multiple Myeloma.F1000Research · 2023Article
- Article
- Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.OncoTargets and therapy · 2021Article
- Pomalidomide and dexamethasone in myelomatous pleural effusion.BMJ case reports · 2020Article
- Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement.Clinical case reports · 2017Article
- Catch me if you can-How to make the best use of pleural effusion.Journal of thoracic disease · 2017Article
- Bilateral myelomatous pleural effusion: presentation of two cases.Blood research · 2016Article
- Flow Cytometry in Diagnosis of Myelomatous Pleural Effusion: A Case Report.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review.Experimental and therapeutic medicine · 2015Article
- Disseminated plasma cell myeloma presenting as massive pleural effusion.European clinical respiratory journal · 2015Article
- Myelomatous pleural effusion as an initial sign of multiple myeloma-a case report and review of literature.Journal of thoracic disease · 2014Article
- Plasma cell myeloma initially presenting as lung cancer.Annals of laboratory medicine · 2013Article
- Plasma Cells Out for a Swim! A Study on Myelomatous Involvement of Effusion Fluid and Cerebrospinal Fluid: A 10-Year Experience from a Tertiary Cancer Center.Journal of cytologyArticle
- Myelomatous Pleural Effusion Presenting with Extreme Hyperferritinemia and Severe Inflammatory Response.Case reports in oncologyArticle
- Transient Pleural Fluid Infiltration by Clonal Plasma Cells Associated with Pulmonary Tuberculosis.Case reports in oncologyArticle
- Myelomatous Pleural Effusion: A Rare Case Report and Literature Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelomatous pleural effusion (MPE) is rare in myeloma patients. We present a consecutive series of patients with MPE in a single institution.
methodsWe retrospectively reviewed the medical records of 19 patients diagnosed with MPE between 1989 and 2008 at the Asan Medical Center. Diagnoses were confirmed by cytologic identification of malignant plasma cells in the pleural fluid.
resultsOur patients showed dominance of IgA (36.8%) and IgD (31.6%) subtypes. Of 734 myeloma patients, the incidence of MPE was remarkably high for the IgD myeloma subtype (16.7%), compared to the other subtypes (1.4% for IgG and 4.6% for IgA). At the time of diagnosis of MPE, elevated serum β2-microglobulin, anemia, elevated serum lactate dehydrogenase, and elevated creatinine levels were found in 100%, 89.5%, 83.3%, and 57.9% of the patients, respectively. Approximately one-third (31.3%) of the patients had adenosine deaminase (ADA) activities in their pleural fluid exceeding the upper limit of the reported cutoff values for tuberculous pleural effusion (55.8 U/L). Chromosome 13 abnormality was seen in 77.8% of the tested patients. The median survival period from the development of MPE was 2.8 months.
conclusionsPatients with MPE have aggressive clinical and laboratory characteristics. The preponderance of IgD myeloma in MPE patients is a noteworthy finding because IgD myeloma is a rare subtype. Elevated ADA activity in the pleural fluid is also noteworthy, and may be helpful for detecting MPE. Physicians treating myeloma patients should monitor the development of MPE and consider the possibility of a worse clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.